Displaying drugs 426 - 450 of 8273 in total
Ceftobiprole
Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA).
The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Description: … medocaril in February 2010, recommending the refusal of its marketing authorization in the European ... activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of ... The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole …
Fidaxomicin
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is...
Approved
Matched Description: … of fidaxomicin. ... diarrhea in adult patients over the age of 18. ... patients over the age of 6 months in the treatment population. …
Artesunate
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin. Artesunate was granted FDA approval on 26 May 2020.
Approved
Investigational
Matched Description: … [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. ... Artesunate is indicated for the initial treatment of severe malaria. …
Viltolarsen
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … restore partial muscle function and slow the progression of DMD. ... Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of ... is characterized by the production of shortened and partially functional dystrophin protein. …
Pregabalin
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects...
Approved
Investigational
Matched Description: … [A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized ... , there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent …
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … treatment of prostate cancer. ... [L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. ... Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several …
Troglitazone
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. …
Meprobamate
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated)....
Approved
Illicit
Matched Description: … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia ... with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Description: … long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Cyproheptadine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of …
Trofinetide
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE ... [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[ …
Butylscopolamine
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic …
Lumiracoxib
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling...
Approved
Investigational
Matched Description: … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the ... FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver …
Olopatadine
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and...
Approved
Matched Description: … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of ... It is a structural analog of [doxepin], which has a minimal anti-allergic activity. ... [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator …
Bimatoprost
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … are synthetic structural analogs of prostaglandin. ... Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast ... [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... [A254387]
The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Estradiol acetate
Estradiol acetate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. ... Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. ... Administration of synthetic and bioidentical forms of estrogen, such as estradiol acetate, has shown …
Zilucoplan
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Matched Description: … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein ... [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized …
Oseltamivir
Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which...
Approved
Matched Description: … The clinical benefit of use of oseltamivir is greatest when administered within 48 hours of the onset ... use of oseltamivir. ... [L7264]
The benefits of oseltamivir use are controversial; a 2014 Cochrane Review of the evidence …
Acetylcysteine
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168]
Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Matched Description: … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of ... [L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications …
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Description: … It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). ... preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. ... approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of …
Enprofylline
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.
Approved
Experimental
Matched Description: … Enprofylline is a derivative of theophylline which shares bronchodilator properties. ... Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular …
Ertapenem
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic …
Displaying drugs 426 - 450 of 8273 in total